Skip to main content

Galantamine Disease Interactions

There are 5 disease interactions with galantamine.

Major

Cholinesterase inhibitor (applies to galantamine) bradycardia

Major Potential Hazard, Moderate plausibility. Applicable conditions: Arrhythmias

Due to their pharmacological action, cholinesterase inhibitors can have a vagotonic effect on the sinoatrial and atrioventricular nodes producing bradycardia or heart block. Therapy with cholinesterase inhibitors should be administered cautiously in patients with preexisting bradycardia or underlying cardiac conduction abnormalities. Syncopal episodes have been reported in patients with and without cardiac abnormalities. Atropine may be used to reverse bradycardia produced by cholinesterase inhibitors.

References

  1. Wilcock GK, Surmon D, Forsyth D, Morgan R "Cholinergic side-effects of tetrahydroaminoacridine." Lancet 2 (1988): 1305
  2. "Product Information. Cognex (tacrine)." Parke-Davis PROD (2001):
  3. Baldessarini RJ, Gelenberg AJ "Using physostigmine safely." Am J Psychiatry 136 (1979): 1608-9
  4. Janowsky DS, Risch SC, Huey LY, Kennedy B, Ziegler M "Effects of physostigmine on pulse, blood pressure, and serum epinephrine levels." Am J Psychiatry 142 (1985): 738-40
  5. Dysken MW, Janowsky DS "Dose-related physostigmine-induced ventricular arrhythmia: case report." J Clin Psychiatry 46 (1985): 446-7
  6. "Product Information. Phospholine Iodide (echothiophate iodide ophthalmic)." Wyeth-Ayerst Laboratories PROD
  7. "Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc PROD (2001):
  8. "Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.
  9. "Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals PROD (2001):
  10. "Product Information. Humorsol Ocumeter (demecarium bromide ophthalmic)." Merck & Co., Inc
  11. "Product Information. Eserine Sulfate Ophthalmic (PHYSostigmine ophthalmic)." Ciba Vision Ophthalmics PROD
  12. "Product Information. Exelon (rivastigmine)." Novartis Pharmaceuticals PROD (2001):
  13. "Product Information. Reminyl (galantamine)." Janssen Pharmaceuticals PROD (2001):
View all 13 references
Major

Cholinesterase inhibitor (applies to galantamine) bronchospasm

Major Potential Hazard, Moderate plausibility. Applicable conditions: Chronic Obstructive Pulmonary Disease, Asthma

Cholinesterase inhibitors inhibit the hydrolysis of acetylcholine. The enhanced effect of acetylcholine produces constriction of the bronchi, increased bronchial secretions, and bronchospasm. Therapy with cholinesterase inhibitors should be administered cautiously in patients with respiratory dysfunction, history of asthma or obstructive pulmonary disease. Monitoring respiratory function during dosage initiation and adjustment is recommended. Use of atropine along with discontinuation of the cholinesterase inhibitor may be required for serious respiratory distress. Neostigmine may produce more severe muscarinic side effects than does pyridostigmine and ambenonium. However, the duration of action is longest for ambenonium and shortest for edrophonium. Echothiophate iodide ophthalmic may be systemically absorbed and cautious use is recommended in these patients.

References

  1. Wilcock GK, Surmon D, Forsyth D, Morgan R "Cholinergic side-effects of tetrahydroaminoacridine." Lancet 2 (1988): 1305
  2. "Product Information. Cognex (tacrine)." Parke-Davis PROD (2001):
  3. "Product Information. Phospholine Iodide (echothiophate iodide ophthalmic)." Wyeth-Ayerst Laboratories PROD
  4. "Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc PROD (2001):
  5. "Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.
  6. "Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals PROD (2001):
  7. "Product Information. Humorsol Ocumeter (demecarium bromide ophthalmic)." Merck & Co., Inc
  8. "Product Information. Eserine Sulfate Ophthalmic (PHYSostigmine ophthalmic)." Ciba Vision Ophthalmics PROD
  9. "Product Information. Exelon (rivastigmine)." Novartis Pharmaceuticals PROD (2001):
  10. "Product Information. Reminyl (galantamine)." Janssen Pharmaceuticals PROD (2001):
View all 10 references
Major

Cholinesterase inhibitor (applies to galantamine) PUD

Major Potential Hazard, Moderate plausibility. Applicable conditions: Peptic Ulcer

The use of cholinesterase inhibitors is associated with an increase in gastric acid secretion and gastric contractions. Therapy with cholinesterase inhibitors should be administered cautiously in patients with peptic ulcer disease.

References

  1. "Product Information. Cognex (tacrine)." Parke-Davis PROD (2001):
  2. "Product Information. Phospholine Iodide (echothiophate iodide ophthalmic)." Wyeth-Ayerst Laboratories PROD
  3. "Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc PROD (2001):
  4. "Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.
  5. "Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals PROD (2001):
  6. "Product Information. Humorsol Ocumeter (demecarium bromide ophthalmic)." Merck & Co., Inc
  7. "Product Information. Eserine Sulfate Ophthalmic (PHYSostigmine ophthalmic)." Ciba Vision Ophthalmics PROD
  8. "Product Information. Exelon (rivastigmine)." Novartis Pharmaceuticals PROD (2001):
  9. "Product Information. Reminyl (galantamine)." Janssen Pharmaceuticals PROD (2001):
View all 9 references
Moderate

Galantamine (applies to galantamine) hepatic impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

In patients with moderate hepatic impairment (Child-Pugh score of 7 to 9), the dosage of galantamine should generally not exceed 16 mg/day. The use of galantamine hydrobromide tablets in patients with severe hepatic impairment (Child-Pugh score of 10 to 15) is not recommended.

References

  1. "Product Information. Reminyl (galantamine)." Janssen Pharmaceuticals PROD (2001):
  2. "Product Information. Razadyne (galantamine)." Johnson and Johnson Medical Inc (2005):
Moderate

Galantamine (applies to galantamine) renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

In patients with creatinine clearance of 9 to 59 mL/min, the dosage of galantamine should generally not exceed 16 mg/day. In patients with creatinine clearance less than 9 mL/min, the use of galantamine hydrobromide tablets is not recommended.

References

  1. "Product Information. Reminyl (galantamine)." Janssen Pharmaceuticals PROD (2001):
  2. "Product Information. Razadyne (galantamine)." Johnson and Johnson Medical Inc (2005):

Galantamine drug interactions

There are 372 drug interactions with galantamine.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.